Novo A/S
Insider CIK 1388325 · BMTI 10% owner · HTGM 10% owner · APEN 10% owner · INGN 10% owner · TBRA 10% owner · CLCD 10% owner · KALV 10% owner · RETA 10% owner · ANAB 10% owner · IRTC 10% owner · MIST 10% owner · OPHT 10% owner · FLXN 10% owner · ALDR 10% owner · NVRO 10% owner · UTRS 10% owner · ZSPH 10% owner · RARX 10% owner · OTIC 10% owner · AKBA 10% owner · AVLN 10% owner · GRTX 10% owner · CRVS 10% owner · RPHM 10% owner · BOLT 10% owner · CMPI 10% owner · CYT 10% owner · MORF 10% owner · SPRB 10% owner · PRAX 10% owner · INZY 10% owner · EWTX 10% owner · EAR 10% owner · ETTX 10% owner · MIRM 10% owner · MPLT 10% owner · MGX 10% owner · ACLX 10% owner · NKTX 10% owner · ALGS 10% owner · GLTO 10% owner · HRMY 10% owner · IRON 10% owner · VERV 10% owner · IOBT 10% owner · COAG 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| COAG Hemab Therapeutics Holding | C Conversion deriv | 2026-05-04 | 2026-05-06 | 23,343 | — | $0 | 0 | SEC↗ |
| COAG Hemab Therapeutics Holding | C Conversion deriv | 2026-05-04 | 2026-05-06 | 71,866 | — | $0 | 0 | SEC↗ |
| COAG Hemab Therapeutics Holding | C Conversion deriv | 2026-05-04 | 2026-05-06 | 62,121 | — | $0 | 0 | SEC↗ |
| COAG Hemab Therapeutics Holding | C Conversion deriv | 2026-05-04 | 2026-05-06 | 32,695 | — | $0 | 0 | SEC↗ |
| COAG Hemab Therapeutics Holding | C Conversion | 2026-05-04 | 2026-05-06 | 4,180,550 | — | $0 | 4,180,550 | SEC↗ |
| AVLN Avalyn Pharma Inc. | C Conversion deriv | 2026-05-01 | 2026-05-05 | 12,558,081 | — | $0 | 0 | SEC↗ |
| AVLN Avalyn Pharma Inc. | C Conversion deriv | 2026-05-01 | 2026-05-05 | 5,587,603 | — | $0 | 0 | SEC↗ |
| AVLN Avalyn Pharma Inc. | C Conversion deriv | 2026-05-01 | 2026-05-05 | 18,000,000 | — | $0 | 0 | SEC↗ |
| AVLN Avalyn Pharma Inc. | C Conversion deriv | 2026-05-01 | 2026-05-05 | 1,986,369 | — | $0 | 0 | SEC↗ |
| AVLN Avalyn Pharma Inc. | C Conversion deriv | 2026-05-01 | 2026-05-05 | 25,899,284 | — | $0 | 0 | SEC↗ |
| AVLN Avalyn Pharma Inc. | P Buy | 2026-05-01 | 2026-05-05 | 555,555 | $18.00 | $10.00M | 3,883,289 | SEC↗ |
| AVLN Avalyn Pharma Inc. | C Conversion | 2026-05-01 | 2026-05-05 | 3,327,734 | — | $0 | 3,327,734 | SEC↗ |
| MPLT MapLight Therapeutics, Inc | C Conversion deriv | 2025-10-28 | 2025-10-30 | 26,191,207 | — | $0 | 0 | SEC↗ |
| MPLT MapLight Therapeutics, Inc | C Conversion deriv | 2025-10-28 | 2025-10-30 | 19,734,671 | — | $0 | 0 | SEC↗ |
| MPLT MapLight Therapeutics, Inc | C Conversion | 2025-10-28 | 2025-10-30 | 2,733,681 | — | $0 | 2,733,681 | SEC↗ |
| MPLT MapLight Therapeutics, Inc | P Buy | 2025-10-28 | 2025-10-30 | 952,941 | $17.00 | $16.20M | 3,686,622 | SEC↗ |
| IOBT IO Biotech, Inc. | S Sale | 2024-07-26 | 2024-07-26 | 23,478 | $1.31 | $30.8K | 4,354,449 | SEC↗ |
| IOBT IO Biotech, Inc. | S Sale | 2024-07-25 | 2024-07-26 | 51,522 | $1.33 | $68.5K | 4,377,927 | SEC↗ |
| IOBT IO Biotech, Inc. | S Sale | 2024-05-10 | 2024-05-14 | 658,809 | $1.22 | $803.7K | 4,429,449 | SEC↗ |
| SPRB SPRUCE BIOSCIENCES, INC. | S Sale | 2024-03-21 | 2024-03-25 | 465,021 | $0.75 | $348.8K | 2,550,000 | SEC↗ |
| SPRB SPRUCE BIOSCIENCES, INC. | S Sale | 2024-03-20 | 2024-03-20 | 359,979 | $0.73 | $262.8K | 3,015,021 | SEC↗ |
| SPRB SPRUCE BIOSCIENCES, INC. | S Sale | 2024-03-19 | 2024-03-20 | 593,000 | $0.76 | $450.7K | 3,375,000 | SEC↗ |
| SPRB SPRUCE BIOSCIENCES, INC. | S Sale | 2024-03-18 | 2024-03-20 | 842,020 | $0.77 | $648.4K | 3,968,000 | SEC↗ |
| SPRB SPRUCE BIOSCIENCES, INC. | S Sale | 2024-03-14 | 2024-03-18 | 1,912,316 | $0.89 | $1.70M | 4,810,020 | SEC↗ |
| MGX Metagenomi, Inc. | C Conversion deriv | 2024-02-13 | 2024-02-15 | 691,760 | — | $0 | 0 | SEC↗ |
| MGX Metagenomi, Inc. | C Conversion deriv | 2024-02-13 | 2024-02-15 | 147,415 | — | $0 | 0 | SEC↗ |
| MGX Metagenomi, Inc. | C Conversion | 2024-02-13 | 2024-02-15 | 839,175 | — | $0 | 939,175 | SEC↗ |
| MGX Metagenomi, Inc. | P Buy | 2024-02-13 | 2024-02-15 | 800,000 | $15.00 | $12.00M | 1,739,175 | SEC↗ |
| IOBT IO Biotech, Inc. | S Sale | 2024-02-09 | 2024-02-13 | 658,809 | $1.50 | $988.2K | 5,088,258 | SEC↗ |
| MGX Metagenomi, Inc. | P Buy | 2024-02-09 | 2024-02-15 | 100,000 | $10.25 | $1.02M | 100,000 | SEC↗ |
| IOBT IO Biotech, Inc. | P Buy deriv | 2023-08-09 | 2023-08-11 | 2,469,135 | $2.03 | $5.01M | 2,469,135 | SEC↗ |
| IOBT IO Biotech, Inc. | P Buy | 2023-08-09 | 2023-08-11 | 2,469,135 | $2.03 | $5.01M | 5,707,467 | SEC↗ |
| CYT Cyteir Therapeutics, Inc. | S Sale | 2023-07-20 | 2023-07-20 | 100,000 | $2.75 | $275.0K | 3,522,136 | SEC↗ |
| CYT Cyteir Therapeutics, Inc. | S Sale | 2023-07-19 | 2023-07-20 | 1,900 | $2.76 | $5.2K | 3,622,136 | SEC↗ |
| CYT Cyteir Therapeutics, Inc. | S Sale | 2023-07-18 | 2023-07-18 | 6,500 | $2.76 | $17.9K | 3,624,036 | SEC↗ |
| CYT Cyteir Therapeutics, Inc. | S Sale | 2023-07-17 | 2023-07-18 | 21,100 | $2.75 | $58.0K | 3,630,536 | SEC↗ |
| CYT Cyteir Therapeutics, Inc. | S Sale | 2023-07-14 | 2023-07-18 | 11,000 | $2.74 | $30.1K | 3,651,636 | SEC↗ |
| CYT Cyteir Therapeutics, Inc. | S Sale | 2023-06-30 | 2023-07-03 | 200,937 | $2.63 | $528.5K | 3,662,636 | SEC↗ |
| IRON Disc Medicine, Inc. | S Sale | 2023-06-28 | 2023-06-28 | 1,250,000 | $46.10 | $57.63M | 1,090,772 | SEC↗ |
| CYT Cyteir Therapeutics, Inc. | S Sale | 2023-06-27 | 2023-06-28 | 31,978 | $1.77 | $56.6K | 3,863,573 | SEC↗ |
| CYT Cyteir Therapeutics, Inc. | S Sale | 2023-06-26 | 2023-06-28 | 8,437 | $1.79 | $15.1K | 3,895,551 | SEC↗ |
| RPHM Reneo Pharmaceuticals, Inc | S Sale | 2023-06-23 | 2023-06-23 | 100,000 | $7.10 | $710.0K | 3,330,337 | SEC↗ |
| CYT Cyteir Therapeutics, Inc. | S Sale | 2023-06-23 | 2023-06-23 | 3,423 | $1.88 | $6.4K | 3,903,988 | SEC↗ |
| CYT Cyteir Therapeutics, Inc. | S Sale | 2023-06-22 | 2023-06-23 | 5,041 | $1.94 | $9.8K | 3,907,411 | SEC↗ |
| CYT Cyteir Therapeutics, Inc. | S Sale | 2023-06-21 | 2023-06-23 | 4,834 | $1.99 | $9.6K | 3,912,452 | SEC↗ |
| CYT Cyteir Therapeutics, Inc. | S Sale | 2023-06-20 | 2023-06-20 | 744 | $2.11 | $1.6K | 3,917,286 | SEC↗ |
| CYT Cyteir Therapeutics, Inc. | S Sale | 2023-06-16 | 2023-06-20 | 5,983 | $2.03 | $12.1K | 3,918,030 | SEC↗ |
| CYT Cyteir Therapeutics, Inc. | S Sale | 2023-06-15 | 2023-06-20 | 10,002 | $2.03 | $20.3K | 3,924,013 | SEC↗ |
| CYT Cyteir Therapeutics, Inc. | S Sale | 2023-06-14 | 2023-06-14 | 2,872 | $2.11 | $6.1K | 3,934,015 | SEC↗ |
| CYT Cyteir Therapeutics, Inc. | S Sale | 2023-06-13 | 2023-06-14 | 2,626 | $2.10 | $5.5K | 3,936,887 | SEC↗ |
| CYT Cyteir Therapeutics, Inc. | S Sale | 2023-06-12 | 2023-06-14 | 900 | $2.06 | $1.9K | 3,939,513 | SEC↗ |
| SPRB SPRUCE BIOSCIENCES, INC. | P Buy deriv | 2023-02-16 | 2023-02-21 | 1,656,000 | — | $0 | 1,656,000 | SEC↗ |
| SPRB SPRUCE BIOSCIENCES, INC. | P Buy | 2023-02-16 | 2023-02-21 | 2,208,000 | $3.17 | $7.00M | 6,722,336 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | P Buy | 2022-09-14 | 2022-09-16 | 484,496 | $10.32 | $5.00M | 6,071,703 | SEC↗ |
| CYT Cyteir Therapeutics, Inc. | S Sale | 2022-07-20 | 2022-07-22 | 900,000 | $3.00 | $2.70M | 3,940,413 | SEC↗ |
| BOLT Bolt Biotherapeutics, Inc. | S Sale | 2022-07-13 | 2022-07-15 | 800,000 | $2.00 | $1.60M | 3,703,991 | SEC↗ |
| CMPI Checkmate Pharmaceuticals, | S Sale | 2022-02-25 | 2022-02-25 | 300 | $2.70 | $810 | 2,161,990 | SEC↗ |
| CMPI Checkmate Pharmaceuticals, | S Sale | 2022-02-24 | 2022-02-25 | 5,990 | $2.83 | $17.0K | 2,162,290 | SEC↗ |
| CMPI Checkmate Pharmaceuticals, | S Sale | 2022-02-23 | 2022-02-25 | 1,820 | $2.90 | $5.3K | 2,168,280 | SEC↗ |
| ACLX Arcellx, Inc. | C Conversion deriv | 2022-02-08 | 2022-02-09 | 533,389 | — | $0 | 0 | SEC↗ |
| ACLX Arcellx, Inc. | C Conversion deriv | 2022-02-08 | 2022-02-09 | 666,651 | — | $0 | 0 | SEC↗ |
| ACLX Arcellx, Inc. | C Conversion deriv | 2022-02-08 | 2022-02-09 | 433,196 | — | $0 | 0 | SEC↗ |
| ACLX Arcellx, Inc. | C Conversion deriv | 2022-02-08 | 2022-02-09 | 1,550,309 | — | $0 | 0 | SEC↗ |
| ACLX Arcellx, Inc. | C Conversion | 2022-02-08 | 2022-02-09 | 3,183,545 | — | $0 | 3,183,545 | SEC↗ |
| ACLX Arcellx, Inc. | P Buy | 2022-02-08 | 2022-02-09 | 833,333 | $15.00 | $12.50M | 4,016,878 | SEC↗ |
| IOBT IO Biotech, Inc. | C Conversion deriv | 2021-11-09 | 2021-11-10 | 75,267 | — | $0 | 0 | SEC↗ |
| IOBT IO Biotech, Inc. | C Conversion deriv | 2021-11-09 | 2021-11-10 | 217,107 | — | $0 | 0 | SEC↗ |
| IOBT IO Biotech, Inc. | C Conversion | 2021-11-09 | 2021-11-10 | 2,952,932 | — | $0 | 2,952,932 | SEC↗ |
| IOBT IO Biotech, Inc. | P Buy | 2021-11-09 | 2021-11-10 | 325,000 | $14.00 | $4.55M | 3,277,932 | SEC↗ |
| UTRS MINERVA SURGICAL INC | C Conversion deriv | 2021-10-26 | 2021-10-27 | 884,484 | — | $0 | 0 | SEC↗ |
| UTRS MINERVA SURGICAL INC | C Conversion deriv | 2021-10-26 | 2021-10-27 | 0 | — | $0 | 0 | SEC↗ |
| UTRS MINERVA SURGICAL INC | P Buy | 2021-10-26 | 2021-10-27 | 580,000 | $12.00 | $6.96M | 2,057,132 | SEC↗ |
| UTRS MINERVA SURGICAL INC | C Conversion | 2021-10-26 | 2021-10-27 | 884,484 | — | $0 | 884,484 | SEC↗ |
| UTRS MINERVA SURGICAL INC | C Conversion | 2021-10-26 | 2021-10-27 | 592,648 | — | $0 | 1,477,132 | SEC↗ |
| CYT Cyteir Therapeutics, Inc. | C Conversion deriv | 2021-06-22 | 2021-06-23 | 14,000,000 | — | $0 | 0 | SEC↗ |
| CYT Cyteir Therapeutics, Inc. | C Conversion deriv | 2021-06-22 | 2021-06-23 | 1,553,116 | — | $0 | 0 | SEC↗ |
| CYT Cyteir Therapeutics, Inc. | P Buy | 2021-06-22 | 2021-06-23 | 277,777 | $18.00 | $5.00M | 4,840,413 | SEC↗ |
| CYT Cyteir Therapeutics, Inc. | C Conversion | 2021-06-22 | 2021-06-23 | 4,562,636 | — | $0 | 4,562,636 | SEC↗ |
| VERV Verve Therapeutics, Inc. | C Conversion deriv | 2021-06-21 | 2021-06-22 | 443,265 | — | $0 | 0 | SEC↗ |
| VERV Verve Therapeutics, Inc. | C Conversion | 2021-06-21 | 2021-06-22 | 443,265 | — | $0 | 443,265 | SEC↗ |
| VERV Verve Therapeutics, Inc. | P Buy | 2021-06-21 | 2021-06-22 | 350,000 | $19.00 | $6.65M | 793,265 | SEC↗ |
| INGN Inogen Inc | S Sale | 2021-06-02 | 2021-06-03 | 680,000 | $57.32 | $38.98M | 2,079,320 | SEC↗ |
| SPRB SPRUCE BIOSCIENCES, INC. | S Sale | 2021-05-19 | 2021-05-21 | 475,000 | $13.90 | $6.60M | 4,514,336 | SEC↗ |
| RPHM Reneo Pharmaceuticals, Inc | C Conversion deriv | 2021-04-13 | 2021-04-14 | 12,367,054 | — | $0 | 0 | SEC↗ |
| RPHM Reneo Pharmaceuticals, Inc | C Conversion | 2021-04-13 | 2021-04-14 | 2,763,711 | — | $0 | 2,763,711 | SEC↗ |
| RPHM Reneo Pharmaceuticals, Inc | P Buy | 2021-04-13 | 2021-04-14 | 666,666 | $15.00 | $10.00M | 3,430,377 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | C Conversion deriv | 2021-03-30 | 2021-03-31 | 1,952,439 | — | $0 | 0 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | C Conversion deriv | 2021-03-30 | 2021-03-31 | 650,328 | — | $0 | 0 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | C Conversion deriv | 2021-03-30 | 2021-03-31 | 2,359,440 | — | $0 | 0 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | P Buy | 2021-03-30 | 2021-03-31 | 625,000 | $16.00 | $10.00M | 5,587,207 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | C Conversion | 2021-03-30 | 2021-03-31 | 4,962,207 | — | $0 | 4,962,207 | SEC↗ |
| INGN Inogen Inc | S Sale | 2021-03-01 | 2021-03-03 | 790,000 | $49.00 | $38.71M | 2,759,320 | SEC↗ |
| GRTX Galera Therapeutics, Inc. | S Sale | 2021-02-18 | 2021-02-19 | 500,000 | $10.58 | $5.29M | 2,459,021 | SEC↗ |
| BOLT Bolt Biotherapeutics, Inc. | C Conversion deriv | 2021-02-09 | 2021-02-11 | 421,670 | — | $0 | 0 | SEC↗ |
| BOLT Bolt Biotherapeutics, Inc. | C Conversion deriv | 2021-02-09 | 2021-02-11 | 2,050,758 | — | $0 | 0 | SEC↗ |
| BOLT Bolt Biotherapeutics, Inc. | C Conversion deriv | 2021-02-09 | 2021-02-11 | 458,337 | — | $0 | 0 | SEC↗ |
| BOLT Bolt Biotherapeutics, Inc. | C Conversion deriv | 2021-02-09 | 2021-02-11 | 1,096,323 | — | $0 | 0 | SEC↗ |
| BOLT Bolt Biotherapeutics, Inc. | C Conversion | 2021-02-09 | 2021-02-11 | 4,027,088 | — | $0 | 4,103,991 | SEC↗ |
| BOLT Bolt Biotherapeutics, Inc. | P Buy | 2021-02-09 | 2021-02-11 | 400,000 | $20.00 | $8.00M | 4,503,991 | SEC↗ |
| INZY Inozyme Pharma, Inc. | S Sale | 2021-01-28 | 2021-02-01 | 375,000 | $21.00 | $7.88M | 2,194,379 | SEC↗ |
| GLTO Galecto, Inc. | C Conversion deriv | 2020-11-02 | 2020-11-04 | 25,562 | — | $0 | 0 | SEC↗ |
| GLTO Galecto, Inc. | C Conversion deriv | 2020-11-02 | 2020-11-04 | 133,991 | — | $0 | 0 | SEC↗ |
| GLTO Galecto, Inc. | C Conversion deriv | 2020-11-02 | 2020-11-04 | 194,666 | — | $0 | 0 | SEC↗ |
| GLTO Galecto, Inc. | C Conversion deriv | 2020-11-02 | 2020-11-04 | 181,688 | — | $0 | 0 | SEC↗ |
| GLTO Galecto, Inc. | C Conversion deriv | 2020-11-02 | 2020-11-04 | 51,911 | — | $0 | 0 | SEC↗ |
| GLTO Galecto, Inc. | C Conversion deriv | 2020-11-02 | 2020-11-04 | 66,666 | — | $0 | 0 | SEC↗ |
| GLTO Galecto, Inc. | C Conversion deriv | 2020-11-02 | 2020-11-04 | 15,833 | — | $0 | 0 | SEC↗ |
| GLTO Galecto, Inc. | C Conversion deriv | 2020-11-02 | 2020-11-04 | 63,333 | — | $0 | 0 | SEC↗ |
| GLTO Galecto, Inc. | C Conversion deriv | 2020-11-02 | 2020-11-04 | 98,930 | — | $0 | 0 | SEC↗ |
| GLTO Galecto, Inc. | P Buy | 2020-11-02 | 2020-11-04 | 333,333 | $15.00 | $5.00M | 2,497,791 | SEC↗ |
| GLTO Galecto, Inc. | C Conversion | 2020-11-02 | 2020-11-04 | 2,164,458 | — | $0 | 2,164,458 | SEC↗ |
| PRAX Praxis Precision Medicines | C Conversion deriv | 2020-10-20 | 2020-10-21 | 551,794 | — | $0 | 0 | SEC↗ |
| PRAX Praxis Precision Medicines | C Conversion deriv | 2020-10-20 | 2020-10-21 | 4,150,000 | — | $0 | 0 | SEC↗ |
| PRAX Praxis Precision Medicines | C Conversion deriv | 2020-10-20 | 2020-10-21 | 171,410 | — | $0 | 0 | SEC↗ |
| PRAX Praxis Precision Medicines | C Conversion deriv | 2020-10-20 | 2020-10-21 | 352,734 | — | $0 | 0 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | C Conversion deriv | 2020-10-20 | 2020-10-22 | 1,609,493 | — | $0 | 0 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | C Conversion deriv | 2020-10-20 | 2020-10-22 | 241,219 | — | $0 | 0 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | C Conversion deriv | 2020-10-20 | 2020-10-22 | 563,851 | — | $0 | 0 | SEC↗ |
| EAR Eargo, Inc. | C Conversion deriv | 2020-10-20 | 2020-10-22 | 737,071 | — | $0 | 0 | SEC↗ |
| PRAX Praxis Precision Medicines | C Conversion | 2020-10-20 | 2020-10-21 | 2,442,080 | — | $0 | 2,442,080 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | P Buy | 2020-10-20 | 2020-10-22 | 200,000 | $15.00 | $3.00M | 2,614,563 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | C Conversion | 2020-10-20 | 2020-10-22 | 2,414,563 | — | $0 | 2,414,563 | SEC↗ |
| EAR Eargo, Inc. | C Conversion | 2020-10-20 | 2020-10-22 | 737,071 | — | $0 | 737,071 | SEC↗ |
| EAR Eargo, Inc. | P Buy | 2020-10-20 | 2020-10-22 | 150,000 | $18.00 | $2.70M | 887,071 | SEC↗ |
| GRTX Galera Therapeutics, Inc. | S Sale | 2020-10-15 | 2020-10-19 | 450,000 | $11.00 | $4.95M | 2,959,021 | SEC↗ |
| SPRB SPRUCE BIOSCIENCES, INC. | C Conversion deriv | 2020-10-14 | 2020-10-16 | 10,000,000 | — | $0 | 0 | SEC↗ |
| SPRB SPRUCE BIOSCIENCES, INC. | C Conversion deriv | 2020-10-14 | 2020-10-16 | 21,000,000 | — | $0 | 0 | SEC↗ |
| SPRB SPRUCE BIOSCIENCES, INC. | C Conversion | 2020-10-14 | 2020-10-16 | 4,739,336 | — | $0 | 4,739,336 | SEC↗ |
| SPRB SPRUCE BIOSCIENCES, INC. | P Buy | 2020-10-14 | 2020-10-16 | 250,000 | $15.00 | $3.75M | 4,989,336 | SEC↗ |
| HRMY Harmony Biosciences Holdin | C Conversion deriv | 2020-08-21 | 2020-08-25 | 1,860,107 | — | $0 | 0 | SEC↗ |
| HRMY Harmony Biosciences Holdin | C Conversion deriv | 2020-08-21 | 2020-08-25 | 25,000,000 | — | $0 | 0 | SEC↗ |
| HRMY Harmony Biosciences Holdin | C Conversion deriv | 2020-08-21 | 2020-09-04 | 25,000,000 | — | $0 | 0 | SEC↗ |
| HRMY Harmony Biosciences Holdin | C Conversion deriv | 2020-08-21 | 2020-09-04 | 1,860,107 | — | $0 | 0 | SEC↗ |
| HRMY Harmony Biosciences Holdin | C Conversion | 2020-08-21 | 2020-08-25 | 4,277,300 | — | $0 | 4,277,300 | SEC↗ |
| HRMY Harmony Biosciences Holdin | P Buy | 2020-08-21 | 2020-08-25 | 132,503 | $24.00 | $3.18M | 4,409,803 | SEC↗ |
| HRMY Harmony Biosciences Holdin | C Conversion | 2020-08-21 | 2020-09-04 | 3,622,470 | — | $0 | 3,754,973 | SEC↗ |
| CMPI Checkmate Pharmaceuticals, | C Conversion deriv | 2020-08-11 | 2020-08-13 | 12,487,512 | — | $0 | 0 | SEC↗ |
| CMPI Checkmate Pharmaceuticals, | C Conversion | 2020-08-11 | 2020-08-13 | 1,670,100 | — | $0 | 1,670,100 | SEC↗ |
| CMPI Checkmate Pharmaceuticals, | P Buy | 2020-08-11 | 2020-08-13 | 500,000 | $15.00 | $7.50M | 2,170,100 | SEC↗ |
| INZY Inozyme Pharma, Inc. | C Conversion deriv | 2020-07-28 | 2020-07-29 | 1,398,600 | — | $0 | 0 | SEC↗ |
| INZY Inozyme Pharma, Inc. | C Conversion deriv | 2020-07-28 | 2020-07-29 | 15,000,000 | — | $0 | 0 | SEC↗ |
| INZY Inozyme Pharma, Inc. | C Conversion | 2020-07-28 | 2020-07-29 | 2,194,379 | — | $0 | 2,194,379 | SEC↗ |
| INZY Inozyme Pharma, Inc. | P Buy | 2020-07-28 | 2020-07-29 | 375,000 | $16.00 | $6.00M | 2,569,379 | SEC↗ |
| NKTX Nkarta, Inc. | C Conversion deriv | 2020-07-14 | 2020-07-16 | 525,499 | — | $0 | 0 | SEC↗ |
| NKTX Nkarta, Inc. | C Conversion deriv | 2020-07-14 | 2020-07-16 | 1,712,811 | — | $0 | 0 | SEC↗ |
| NKTX Nkarta, Inc. | C Conversion | 2020-07-14 | 2020-07-16 | 2,238,310 | — | $0 | 2,238,310 | SEC↗ |
| NKTX Nkarta, Inc. | P Buy | 2020-07-14 | 2020-07-16 | 555,555 | $18.00 | $10.00M | 2,793,865 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | S Sale | 2020-07-08 | 2020-07-09 | 741,440 | $5.37 | $3.98M | 1,389,498 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | S Sale | 2020-07-07 | 2020-07-09 | 796,622 | $5.25 | $4.18M | 2,130,938 | SEC↗ |
| MIST Milestone Pharmaceuticals | S Sale | 2019-11-25 | 2019-11-27 | 240,000 | $16.00 | $3.84M | 2,434,470 | SEC↗ |
| GRTX Galera Therapeutics, Inc. | C Conversion deriv | 2019-11-12 | 2019-11-14 | 2,709,659 | — | $0 | 0 | SEC↗ |
| GRTX Galera Therapeutics, Inc. | C Conversion deriv | 2019-11-12 | 2019-11-14 | 12,000,000 | — | $0 | 0 | SEC↗ |
| GRTX Galera Therapeutics, Inc. | C Conversion | 2019-11-12 | 2019-11-14 | 535,869 | — | $0 | 2,909,021 | SEC↗ |
| GRTX Galera Therapeutics, Inc. | C Conversion | 2019-11-12 | 2019-11-14 | 2,373,152 | — | $0 | 2,373,152 | SEC↗ |
| GRTX Galera Therapeutics, Inc. | P Buy | 2019-11-12 | 2019-11-14 | 500,000 | $12.00 | $6.00M | 3,409,021 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | S Sale | 2019-07-25 | 2019-07-25 | 1,400,000 | $4.00 | $5.60M | 2,927,560 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | S Sale | 2019-07-24 | 2019-07-25 | 53,240 | $5.01 | $266.7K | 4,327,560 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | S Sale | 2019-07-23 | 2019-07-25 | 39,716 | $5.32 | $211.3K | 4,380,800 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | C Conversion deriv | 2019-07-22 | 2019-07-23 | 1,870,147 | — | $0 | 0 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | P Buy | 2019-07-22 | 2019-07-23 | 575,000 | $15.00 | $8.63M | 2,445,147 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | C Conversion | 2019-07-22 | 2019-07-23 | 1,870,147 | — | $0 | 1,870,147 | SEC↗ |
| MORF Morphic Holding, Inc. | C Conversion deriv | 2019-06-28 | 2019-07-01 | 1,978,779 | — | $0 | 0 | SEC↗ |
| MORF Morphic Holding, Inc. | C Conversion | 2019-06-28 | 2019-07-01 | 1,978,779 | — | $0 | 1,978,779 | SEC↗ |
| MORF Morphic Holding, Inc. | P Buy | 2019-06-28 | 2019-07-01 | 666,667 | $15.00 | $10.00M | 2,645,446 | SEC↗ |
| MIST Milestone Pharmaceuticals | M Exercise deriv | 2019-05-13 | 2019-05-14 | 964,089 | — | $0 | 0 | SEC↗ |
| MIST Milestone Pharmaceuticals | M Exercise deriv | 2019-05-13 | 2019-05-14 | 1,377,048 | — | $0 | 0 | SEC↗ |
| MIST Milestone Pharmaceuticals | P Buy | 2019-05-13 | 2019-05-14 | 333,333 | $15.00 | $5.00M | 2,674,470 | SEC↗ |
| MIST Milestone Pharmaceuticals | M Exercise | 2019-05-13 | 2019-05-14 | 964,089 | — | $0 | 2,341,137 | SEC↗ |
| MIST Milestone Pharmaceuticals | M Exercise | 2019-05-13 | 2019-05-14 | 1,377,048 | — | $0 | 1,377,048 | SEC↗ |
| ETTX Entasis Therapeutics Holdi | C Conversion deriv | 2018-09-28 | 2018-10-01 | 7,000,000 | — | $0 | 0 | SEC↗ |
| ETTX Entasis Therapeutics Holdi | C Conversion deriv | 2018-09-28 | 2018-10-01 | 14,237,288 | — | $0 | 0 | SEC↗ |
| ETTX Entasis Therapeutics Holdi | P Buy | 2018-09-28 | 2018-10-01 | 1,089,835 | $15.00 | $16.35M | 2,181,843 | SEC↗ |
| ETTX Entasis Therapeutics Holdi | C Conversion | 2018-09-28 | 2018-10-01 | 1,092,008 | — | $0 | 1,092,008 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | P Buy | 2018-03-12 | 2018-03-13 | 1,176,470 | $8.50 | $10.00M | 4,420,516 | SEC↗ |
| KALV KalVista Pharmaceuticals, | S Sale | 2017-10-12 | 2017-10-12 | 481 | $10.02 | $4.8K | 1,726,000 | SEC↗ |
| KALV KalVista Pharmaceuticals, | S Sale | 2017-10-12 | 2017-10-12 | 1,726,000 | $8.50 | $14.67M | 0 | SEC↗ |
| KALV KalVista Pharmaceuticals, | S Sale | 2017-10-11 | 2017-10-12 | 35,519 | $10.21 | $362.6K | 1,726,481 | SEC↗ |
| KALV KalVista Pharmaceuticals, | S Sale | 2017-10-10 | 2017-10-12 | 165,199 | $12.32 | $2.04M | 1,955,747 | SEC↗ |
| KALV KalVista Pharmaceuticals, | S Sale | 2017-10-10 | 2017-10-12 | 190,981 | $11.18 | $2.14M | 2,120,946 | SEC↗ |
| KALV KalVista Pharmaceuticals, | S Sale | 2017-10-10 | 2017-10-12 | 413,356 | $10.36 | $4.28M | 2,311,927 | SEC↗ |
| KALV KalVista Pharmaceuticals, | S Sale | 2017-10-10 | 2017-10-12 | 61,044 | $13.39 | $817.4K | 1,894,703 | SEC↗ |
| KALV KalVista Pharmaceuticals, | S Sale | 2017-10-10 | 2017-10-12 | 57,580 | $14.07 | $810.2K | 1,837,123 | SEC↗ |
| KALV KalVista Pharmaceuticals, | S Sale | 2017-10-10 | 2017-10-12 | 75,123 | $15.36 | $1.15M | 1,762,000 | SEC↗ |
| KALV KalVista Pharmaceuticals, | S Sale | 2017-09-15 | 2017-09-15 | 140,744 | $7.00 | $985.2K | 2,725,283 | SEC↗ |
| KALV KalVista Pharmaceuticals, | S Sale | 2017-09-15 | 2017-09-15 | 3 | $8.00 | $24 | 2,725,280 | SEC↗ |
| KALV KalVista Pharmaceuticals, | S Sale | 2017-09-15 | 2017-09-18 | 140,744 | $7.00 | $985.2K | 2,725,283 | SEC↗ |
| KALV KalVista Pharmaceuticals, | S Sale | 2017-09-14 | 2017-09-15 | 10,000 | $8.05 | $80.5K | 2,866,027 | SEC↗ |
| KALV KalVista Pharmaceuticals, | S Sale | 2017-09-14 | 2017-09-18 | 10,000 | $8.05 | $80.5K | 2,866,027 | SEC↗ |
| KALV KalVista Pharmaceuticals, | S Sale | 2017-09-13 | 2017-09-15 | 25,900 | $8.02 | $207.7K | 2,876,027 | SEC↗ |
| KALV KalVista Pharmaceuticals, | S Sale | 2017-09-13 | 2017-09-18 | 25,900 | $8.02 | $207.7K | 2,876,027 | SEC↗ |
| HTGM HTG MOLECULAR DIAGNOSTICS, | S Sale | 2017-08-25 | 2017-08-25 | 720,214 | $1.75 | $1.26M | 0 | SEC↗ |
| HTGM HTG MOLECULAR DIAGNOSTICS, | S Sale | 2017-08-24 | 2017-08-25 | 382,437 | $1.91 | $730.5K | 720,214 | SEC↗ |
| HTGM HTG MOLECULAR DIAGNOSTICS, | S Sale | 2017-08-23 | 2017-08-25 | 47,162 | $2.02 | $95.3K | 1,102,651 | SEC↗ |
| HTGM HTG MOLECULAR DIAGNOSTICS, | S Sale | 2017-08-22 | 2017-08-22 | 12,641 | $2.01 | $25.4K | 1,199,599 | SEC↗ |
| ANAB ANAPTYSBIO INC | S Sale | 2017-08-21 | 2017-08-21 | 356,300 | $21.10 | $7.52M | 1,936,604 | SEC↗ |
| HTGM HTG MOLECULAR DIAGNOSTICS, | S Sale | 2017-08-21 | 2017-08-22 | 12,845 | $2.02 | $25.9K | 1,212,240 | SEC↗ |
| HTGM HTG MOLECULAR DIAGNOSTICS, | S Sale | 2017-08-18 | 2017-08-22 | 55,100 | $2.10 | $115.7K | 1,225,085 | SEC↗ |
| ANAB ANAPTYSBIO INC | S Sale | 2017-08-15 | 2017-08-16 | 143,428 | $21.00 | $3.01M | 2,292,904 | SEC↗ |
| ANAB ANAPTYSBIO INC | S Sale | 2017-08-14 | 2017-08-16 | 35,172 | $21.79 | $766.4K | 2,436,332 | SEC↗ |
| ANAB ANAPTYSBIO INC | S Sale | 2017-08-07 | 2017-08-08 | 480,000 | $21.10 | $10.13M | 2,472,527 | SEC↗ |
| ANAB ANAPTYSBIO INC | S Sale | 2017-08-07 | 2017-08-08 | 1,023 | $22.92 | $23.4K | 2,471,504 | SEC↗ |
| ANAB ANAPTYSBIO INC | S Sale | 2017-08-04 | 2017-08-08 | 10,271 | $22.00 | $226.0K | 2,952,527 | SEC↗ |
| ANAB ANAPTYSBIO INC | S Sale | 2017-08-03 | 2017-08-03 | 21,451 | $22.01 | $472.1K | 2,962,798 | SEC↗ |
| ANAB ANAPTYSBIO INC | S Sale | 2017-08-02 | 2017-08-03 | 25,700 | $23.87 | $613.5K | 2,984,249 | SEC↗ |
| ANAB ANAPTYSBIO INC | S Sale | 2017-08-01 | 2017-08-03 | 23,555 | $23.87 | $562.3K | 3,009,949 | SEC↗ |
| APEN Apollo Endosurgery, Inc. | S Sale | 2017-07-26 | 2017-07-26 | 8,426 | $6.84 | $57.6K | 1,301,842 | SEC↗ |
| APEN Apollo Endosurgery, Inc. | S Sale | 2017-07-25 | 2017-07-26 | 24,504 | $6.96 | $170.5K | 1,310,268 | SEC↗ |
| APEN Apollo Endosurgery, Inc. | S Sale | 2017-07-24 | 2017-07-26 | 17,200 | $6.83 | $117.5K | 1,334,772 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | P Buy | 2017-06-23 | 2017-06-27 | 20,000 | $10.95 | $219.0K | 3,244,046 | SEC↗ |
| RETA REATA PHARMACEUTICALS INC | S Sale deriv | 2017-06-22 | 2017-06-23 | 1,200,000 | $25.00 | $30.00M | 1,201,969 | SEC↗ |
| RETA REATA PHARMACEUTICALS INC | S Sale | 2017-06-14 | 2017-06-14 | 49,611 | $25.03 | $1.24M | 592,794 | SEC↗ |
| RETA REATA PHARMACEUTICALS INC | S Sale | 2017-06-13 | 2017-06-14 | 11,389 | $25.47 | $290.1K | 642,405 | SEC↗ |
| RETA REATA PHARMACEUTICALS INC | S Sale | 2017-06-12 | 2017-06-12 | 90,303 | $25.28 | $2.28M | 653,794 | SEC↗ |
| RETA REATA PHARMACEUTICALS INC | S Sale | 2017-06-09 | 2017-06-12 | 2,200 | $25.89 | $57.0K | 744,097 | SEC↗ |
| RETA REATA PHARMACEUTICALS INC | S Sale | 2017-06-08 | 2017-06-12 | 130,000 | $26.00 | $3.38M | 746,297 | SEC↗ |
| RETA REATA PHARMACEUTICALS INC | S Sale | 2017-06-07 | 2017-06-07 | 2,000 | $28.04 | $56.1K | 876,297 | SEC↗ |
| RETA REATA PHARMACEUTICALS INC | S Sale | 2017-06-06 | 2017-06-07 | 64,170 | $28.09 | $1.80M | 878,297 | SEC↗ |
| RETA REATA PHARMACEUTICALS INC | S Sale | 2017-06-05 | 2017-06-07 | 23,327 | $28.67 | $668.8K | 942,467 | SEC↗ |
| APEN Apollo Endosurgery, Inc. | S Sale | 2017-05-11 | 2017-05-11 | 103,500 | $5.62 | $581.7K | 1,351,972 | SEC↗ |
| APEN Apollo Endosurgery, Inc. | S Sale | 2017-05-10 | 2017-05-11 | 1,500 | $5.74 | $8.6K | 1,455,472 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion deriv | 2017-01-31 | 2017-02-01 | 486,820 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion deriv | 2017-01-31 | 2017-02-01 | 673,454 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion deriv | 2017-01-31 | 2017-02-01 | 1,428,571 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion deriv | 2017-01-31 | 2017-02-01 | 312,986 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO INC | X Exercise deriv | 2017-01-31 | 2017-02-01 | 117,235 | — | $0 | 0 | SEC↗ |
| ANAB ANAPTYSBIO INC | P Buy | 2017-01-31 | 2017-02-01 | 50,000 | $15.00 | $750.0K | 3,033,504 | SEC↗ |
| ANAB ANAPTYSBIO INC | X Exercise | 2017-01-31 | 2017-02-01 | 81,673 | — | $0 | 2,983,504 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion | 2017-01-31 | 2017-02-01 | 673,454 | — | $0 | 2,901,831 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion | 2017-01-31 | 2017-02-01 | 312,986 | — | $0 | 2,228,377 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion | 2017-01-31 | 2017-02-01 | 486,820 | — | $0 | 1,915,391 | SEC↗ |
| ANAB ANAPTYSBIO INC | C Conversion | 2017-01-31 | 2017-02-01 | 1,428,571 | — | $0 | 1,428,571 | SEC↗ |
| OPHT Ophthotech Corp. | S Sale | 2016-12-15 | 2016-12-16 | 1,405,487 | $4.72 | $6.63M | 0 | SEC↗ |
| OPHT Ophthotech Corp. | S Sale | 2016-12-14 | 2016-12-16 | 2,205,000 | $4.97 | $10.96M | 1,405,487 | SEC↗ |
| RARX Ra Pharmaceuticals, Inc. | C Conversion deriv | 2016-10-31 | 2016-11-02 | 860,438 | — | $0 | 0 | SEC↗ |
| RARX Ra Pharmaceuticals, Inc. | C Conversion deriv | 2016-10-31 | 2016-11-02 | 924,970 | — | $0 | 0 | SEC↗ |
| RARX Ra Pharmaceuticals, Inc. | C Conversion | 2016-10-31 | 2016-11-02 | 924,970 | — | $0 | 924,970 | SEC↗ |
| RARX Ra Pharmaceuticals, Inc. | C Conversion | 2016-10-31 | 2016-11-02 | 860,438 | — | $0 | 1,785,408 | SEC↗ |
| RARX Ra Pharmaceuticals, Inc. | P Buy | 2016-10-31 | 2016-11-02 | 246,154 | $13.00 | $3.20M | 2,031,562 | SEC↗ |
| IRTC iRhythm Technologies, Inc. | C Conversion deriv | 2016-10-25 | 2016-10-26 | 2,007,449 | — | $0 | 0 | SEC↗ |
| IRTC iRhythm Technologies, Inc. | C Conversion | 2016-10-25 | 2016-10-26 | 2,007,449 | — | $0 | 2,024,448 | SEC↗ |
| IRTC iRhythm Technologies, Inc. | P Buy | 2016-10-25 | 2016-10-26 | 100,000 | $17.00 | $1.70M | 2,124,448 | SEC↗ |
| CLCD CoLucid Pharmaceuticals, I | P Buy | 2016-09-09 | 2016-09-13 | 100,000 | $20.00 | $2.00M | 3,156,563 | SEC↗ |
| TBRA Tobira Therapeutics, Inc. | S Sale | 2016-07-13 | 2016-07-13 | 29,884 | $11.88 | $355.0K | 1,875,905 | SEC↗ |
| TBRA Tobira Therapeutics, Inc. | S Sale | 2016-07-12 | 2016-07-13 | 8,752 | $12.12 | $106.1K | 1,905,789 | SEC↗ |
| TBRA Tobira Therapeutics, Inc. | S Sale | 2016-07-11 | 2016-07-13 | 20,431 | $12.19 | $249.1K | 1,914,541 | SEC↗ |
| TBRA Tobira Therapeutics, Inc. | S Sale | 2016-07-07 | 2016-07-07 | 21,869 | $12.03 | $263.1K | 1,934,972 | SEC↗ |
| TBRA Tobira Therapeutics, Inc. | S Sale | 2016-07-06 | 2016-07-07 | 59,850 | $12.20 | $730.2K | 1,956,841 | SEC↗ |
| TBRA Tobira Therapeutics, Inc. | S Sale | 2016-07-05 | 2016-07-07 | 10,400 | $12.57 | $130.7K | 2,016,691 | SEC↗ |
| TBRA Tobira Therapeutics, Inc. | S Sale | 2016-06-30 | 2016-06-30 | 27,133 | $12.58 | $341.3K | 2,027,091 | SEC↗ |
| TBRA Tobira Therapeutics, Inc. | S Sale | 2016-06-29 | 2016-06-30 | 16,068 | $12.63 | $202.9K | 2,054,224 | SEC↗ |
| TBRA Tobira Therapeutics, Inc. | S Sale | 2016-06-28 | 2016-06-30 | 20,883 | $13.77 | $287.6K | 2,073,022 | SEC↗ |
| TBRA Tobira Therapeutics, Inc. | S Sale | 2016-06-28 | 2016-06-30 | 2,730 | $14.28 | $39.0K | 2,070,292 | SEC↗ |
| TBRA Tobira Therapeutics, Inc. | S Sale | 2016-06-06 | 2016-06-07 | 187,500 | $10.37 | $1.94M | 2,093,905 | SEC↗ |
| RETA REATA PHARMACEUTICALS INC | C Conversion deriv | 2016-06-01 | 2016-08-05 | 215,794 | — | $0 | 2,401,969 | SEC↗ |
| RETA REATA PHARMACEUTICALS INC | C Conversion | 2016-06-01 | 2016-08-05 | 215,794 | — | $0 | 965,794 | SEC↗ |
| RETA REATA PHARMACEUTICALS INC | P Buy | 2016-06-01 | 2016-06-02 | 750,000 | $11.00 | $8.25M | 750,000 | SEC↗ |
| OPHT Ophthotech Corp. | S Sale | 2016-05-24 | 2016-05-25 | 1,300,000 | $49.00 | $63.70M | 3,610,489 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | P Buy | 2016-05-12 | 2016-05-16 | 70,000 | $10.00 | $700.0K | 3,224,046 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | C Conversion deriv | 2016-03-29 | 2016-03-30 | 356,888 | — | $0 | 0 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | C Conversion deriv | 2016-03-29 | 2016-03-30 | 2,130,492 | — | $0 | 0 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | P Buy | 2016-03-29 | 2016-03-30 | 666,666 | $15.00 | $10.00M | 3,154,046 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | C Conversion | 2016-03-29 | 2016-03-30 | 2,130,492 | — | $0 | 2,130,492 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | C Conversion | 2016-03-29 | 2016-03-30 | 356,888 | — | $0 | 2,487,380 | SEC↗ |
| TBRA Tobira Therapeutics, Inc. | S Sale | 2016-03-04 | 2016-03-04 | 55,000 | $6.54 | $359.7K | 2,281,405 | SEC↗ |
| TBRA Tobira Therapeutics, Inc. | S Sale | 2016-03-03 | 2016-03-04 | 25,000 | $6.86 | $171.5K | 2,336,405 | SEC↗ |
| TBRA Tobira Therapeutics, Inc. | S Sale | 2016-03-02 | 2016-03-04 | 110,000 | $6.92 | $761.2K | 2,361,405 | SEC↗ |
| TBRA Tobira Therapeutics, Inc. | S Sale | 2015-11-18 | 2015-11-19 | 153,601 | $9.76 | $1.50M | 2,471,405 | SEC↗ |
| TBRA Tobira Therapeutics, Inc. | S Sale | 2015-11-17 | 2015-11-19 | 71,399 | $9.87 | $704.7K | 2,625,006 | SEC↗ |
| FLXN Flexion Therapeutics Inc | S Sale | 2015-06-22 | 2015-06-22 | 63,412 | $20.55 | $1.30M | 2,133,131 | SEC↗ |
| FLXN Flexion Therapeutics Inc | S Sale | 2015-06-19 | 2015-06-22 | 50,888 | $20.07 | $1.02M | 2,196,543 | SEC↗ |
| FLXN Flexion Therapeutics Inc | S Sale | 2015-06-18 | 2015-06-22 | 35,700 | $21.51 | $767.9K | 2,247,431 | SEC↗ |
| CLCD CoLucid Pharmaceuticals, I | C Conversion deriv | 2015-05-11 | 2015-05-12 | 1,756,563 | — | $0 | 0 | SEC↗ |
| HTGM HTG MOLECULAR DIAGNOSTICS, | C Conversion deriv | 2015-05-11 | 2015-05-12 | 156,123 | — | $0 | 0 | SEC↗ |
| HTGM HTG MOLECULAR DIAGNOSTICS, | C Conversion deriv | 2015-05-11 | 2015-05-12 | 110,755 | — | $0 | 0 | SEC↗ |
| HTGM HTG MOLECULAR DIAGNOSTICS, | X Exercise deriv | 2015-05-11 | 2015-05-12 | 49,786 | — | $0 | 0 | SEC↗ |
| HTGM HTG MOLECULAR DIAGNOSTICS, | C Conversion deriv | 2015-05-11 | 2015-05-12 | 598,415 | — | $0 | 0 | SEC↗ |
| CLCD CoLucid Pharmaceuticals, I | P Buy | 2015-05-11 | 2015-05-12 | 1,300,000 | $10.00 | $13.00M | 3,056,563 | SEC↗ |
| CLCD CoLucid Pharmaceuticals, I | C Conversion | 2015-05-11 | 2015-05-12 | 1,756,563 | — | $0 | 1,756,563 | SEC↗ |
| HTGM HTG MOLECULAR DIAGNOSTICS, | C Conversion | 2015-05-11 | 2015-05-12 | 110,755 | — | $0 | 865,293 | SEC↗ |
| HTGM HTG MOLECULAR DIAGNOSTICS, | X Exercise | 2015-05-11 | 2015-05-12 | 49,786 | — | $0 | 915,079 | SEC↗ |
| HTGM HTG MOLECULAR DIAGNOSTICS, | P Buy | 2015-05-11 | 2015-05-12 | 365,106 | $14.00 | $5.11M | 1,280,185 | SEC↗ |
| HTGM HTG MOLECULAR DIAGNOSTICS, | C Conversion | 2015-05-11 | 2015-05-12 | 754,538 | — | $0 | 754,538 | SEC↗ |
| TBRA Tibira Therapeutics, Inc. | P Buy | 2015-05-04 | 2015-05-06 | 838,041 | $10.62 | $8.90M | 2,696,405 | SEC↗ |
| OPHT Ophthotech Corp. | X Exercise deriv | 2015-03-25 | 2015-03-26 | 13,668 | — | $0 | 0 | SEC↗ |
| OPHT Ophthotech Corp. | X Exercise | 2015-03-25 | 2015-03-26 | 13,668 | $0.06 | $820 | 4,910,487 | SEC↗ |
| OPHT Ophthotech Corp. | S Sale | 2015-03-05 | 2015-03-09 | 1,005,000 | $51.75 | $52.01M | 4,896,819 | SEC↗ |
| FLXN Flexion Therapeutics Inc | P Buy | 2014-12-17 | 2014-12-18 | 500,000 | $17.00 | $8.50M | 2,283,131 | SEC↗ |
| OPHT Ophthotech Corp. | S Sale | 2014-11-13 | 2014-11-17 | 995,000 | $40.20 | $40.00M | 5,901,819 | SEC↗ |
| NVRO NEVRO CORP | C Conversion deriv | 2014-11-12 | 2014-11-13 | 1,979,841 | — | $0 | 0 | SEC↗ |
| NVRO NEVRO CORP | P Buy | 2014-11-12 | 2014-11-13 | 215,000 | $18.00 | $3.87M | 2,194,841 | SEC↗ |
| NVRO NEVRO CORP | C Conversion | 2014-11-12 | 2014-11-13 | 1,979,841 | — | $0 | 1,979,841 | SEC↗ |
| INGN Inogen Inc | S Sale | 2014-11-04 | 2014-11-05 | 2,000,000 | $21.50 | $43.00M | 3,549,320 | SEC↗ |
| INGN Inogen Inc | X Exercise deriv | 2014-10-15 | 2014-10-17 | 2,727 | — | $0 | 0 | SEC↗ |
| INGN Inogen Inc | X Exercise deriv | 2014-10-15 | 2014-10-17 | 52,018 | — | $0 | 0 | SEC↗ |
| INGN Inogen Inc | X Exercise deriv | 2014-10-15 | 2014-10-17 | 11,488 | — | $0 | 0 | SEC↗ |
| INGN Inogen Inc | X Exercise deriv | 2014-10-15 | 2014-10-17 | 5,570 | — | $0 | 0 | SEC↗ |
| INGN Inogen Inc | X Exercise deriv | 2014-10-15 | 2014-10-17 | 26,365 | — | $0 | 0 | SEC↗ |
| INGN Inogen Inc | X Exercise deriv | 2014-10-15 | 2014-10-17 | 19,022 | — | $0 | 0 | SEC↗ |
| INGN Inogen Inc | X Exercise deriv | 2014-10-15 | 2014-10-17 | 12,681 | — | $0 | 0 | SEC↗ |
| INGN Inogen Inc | X Exercise | 2014-10-15 | 2014-10-17 | 129,871 | $38961.30 | $5.06B | 5,549,320 | SEC↗ |